Today, more than 50 percent of cancer patients can be cured with conventional treatments – that is, therapies with a proven response rate. However, there are many patients who do not respond to standard treatment and may be eligible for participation in our Phase I clinical trials program.
What Are Phase I Clinical Trials?
Phase I trials are the cornerstone for advancement of new therapies. A Phase I trial represents the clinical starting point for all new drugs that ultimately receive FDA approval and often represents the first time a drug or compound is being tested in humans.
A Phase I study is designed to test a potential anticancer compound that has shown promising results in the laboratory in a small population of cancer patients.
For researchers, the goal is to evaluate the compound’s overall safety, determine a safe dosage range, and identify side effects. It also allows researchers to study how the drug will act in the body and whether or not it gives benefit to patients.
For patients, participating in a Phase I clinical trial gives them access to some of the latest cancer treatments. Patients who go on these studies are true pioneers as their participation may lead to groundbreaking data that can ultimately lead to newer and better drugs for patients with advanced cancer.
This is where START Madrid is making true inroads into the advancement of cancer care as our research efforts are resulting in the accelerated development of such therapies. Ultimately, these drugs result in better quality of life and survival for patients living with cancer.